Abstract
It has been more than 30 years since the discovery of human T-lymphotropic virus type 1 (HTLV-1), the first human retrovirus identified. Human T-lymphotropic virus type 1 infects 15-20 million people worldwide causing two major diseases: adult T-cell leukemia/lymphoma and HTLV-1-associated myelopathy/tropical spastic paraparesis. Human T-lymphotropic virus type 1 establishes several decades of latent infection, during which viral-host interaction determines disease segregation. This review highlights non-structural proteins that are encoded on the viral genome and manage latent infection. Latent infection is a key in HTLV pathology, so that effective inhibition of these proteins might lead to successful disease management. © 2013 Japanese Cancer Association.
Cite
CITATION STYLE
Fukumoto, R. (2013, August). Human T-lymphotropic virus type 1 non-structural proteins: Requirements for latent Infection. Cancer Science. https://doi.org/10.1111/cas.12190
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.